Sign In
Buy AKRO
$54.65
+0 (+0%)
At Close: Mar 06, 2026
Why Akero Therapeutics Stock Trounced the Market on Thursday
04:48pm, Thursday, 09'th Oct 2025
One of the best catalysts for sudden, sharp rise in the price of a stock is when the company behind it get acquired at a premium. Case in point: Akero Therapeutics (AKRO 16.33%), whose shares soared b
Top Stock Movers Now: Delta Air Lines, PepsiCo, Akero Therapeutics, and More
01:05pm, Thursday, 09'th Oct 2025
Major U.S. equities indexes pulled back Thursday after the S&P 500 and Nasdaq set fresh all-time highs. The Dow Jones Industrial Average, S&P 500, and Nasdaq all were lower at midday.
Shareholder Alert: The Ademi Firm investigates whether Akero Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders
11:00am, Thursday, 09'th Oct 2025
MILWAUKEE , Oct. 9, 2025 /PRNewswire/ -- The Ademi Firm is investigating Akero (NASDAQ: AKRO) for possible breaches of fiduciary duty and other violations of law in its transaction with Novo Nordisk.
Novo Nordisk to acquire Akero Therapeutics for its experimental liver disease drug
10:21am, Thursday, 09'th Oct 2025
Novo Nordisk said on Thursday it would buy U.S.-based Akero Therapeutics for up to $5.2 billion to add its promising experimental liver disease drug, in the first major deal by the Danish drugmaker's
Akero Therapeutics Stock Surges on Novo Nordisk Buyout
10:11am, Thursday, 09'th Oct 2025
Novo Nordisk A/S (NYSE:NVO) is down 1% to trade at $59 this morning, after news surfaced that the pharmaceutical concern has entered an agreement to purchase U.S.-based peer Akero Therapeutics Inc (NA
Novo Nordisk To Acquire Liver Disease Focused Akero Therapeutics For Around $5 Billion
09:10am, Thursday, 09'th Oct 2025
Novo Nordisk A/S (NYSE:NVO) agreed on Thursday to acquire Akero Therapeutics, Inc. (NASDAQ:AKRO) focused on metabolic diseases.
Novo Nordisk acquires Akero Therapeutics and its promising liver therapy for up to $5.2B
08:54am, Thursday, 09'th Oct 2025
Novo Nordisk (NYSE:NVO) announced it is acquiring Akero Therapeutics (NASDAQ: AKRO) for a total potential value of up to $5.2 billion, strengthening its pipeline in treatments for metabolic dysfunct
AKRO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Akero Therapeutics, Inc. Is Fair to Shareholders
08:00am, Thursday, 09'th Oct 2025
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Akero Therapeutics, Inc. (NASDAQ: AKRO) to Novo Nordisk A/S is fair to Akero shareholders
Akero Therapeutics Stock Soars on Novo Nordisk Deal.
07:31am, Thursday, 09'th Oct 2025
Novo said it would buy Akero for $54 a share in cash and an additional $6 if it gets U.S. approval of Efruxifermin - it's treatment for fatty liver disease.
Novo Nordisk To Buy Akero Therapeutics for $4.7 Billion
06:39am, Thursday, 09'th Oct 2025
Novo said the acquisition of would contribute to its strategy to develop medicines for people living with diabetes, obesity and their associated comorbidities.
Novo Nordisk buys Akero Therapeutics in the US
06:09am, Thursday, 09'th Oct 2025
Danish drugmaker Novo Nordisk said on Thursday it had agreed to buy United States based Akero Therapeutics, a clinical-stage company developing innovative treatments for patients with serious metaboli
Akero Therapeutics to be Acquired by Novo Nordisk for up to $5.2 Billion
06:01am, Thursday, 09'th Oct 2025
Shareholders to Receive $54 Per Share in Cash and CVR of $6 Per Share Advances Akero's Mission of Bringing Novel Therapies to Patients with High Unmet Medical Needs SOUTH SAN FRANCISCO, Calif., Oct.
Novo Nordisk to acquire Akero Therapeutics and its promising phase 3 FGF21 analogue to expand MASH portfolio
06:00am, Thursday, 09'th Oct 2025
Bagsværd, Denmark, 9 October, 2025 – Novo Nordisk today announced that it has entered into a definitive agreement to acquire Akero Therapeutics, Inc. (Akero), a publicly held clinical-stage company
SOUTH SAN FRANCISCO, Calif., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabo
Is Akero Therapeutics (AKRO) Stock Outpacing Its Medical Peers This Year?
10:41am, Wednesday, 01'st Oct 2025
Here is how Akero Therapeutics, Inc. (AKRO) and Humana (HUM) have performed compared to their sector so far this year.
